ImPACT Applications has introduced new FDA-approved pediatric medical device for concussion management.
Impact Pediatric, which is designed for individuals from age 5 to 11, provides health care professionals with objective measures of neurocognitive functioning for evaluation and management of concussion in younger children.
ImPACT Pediatric is an iPad-based computerized test, which is individually administered, helping to engage children easily in a clinical setting.
The device can effectively measure neurocognitive function in the children, according to the company.
In addition, the company provides FDA-approved ImPACT computerized neurocognitive concussion assessment and management tool for concussion management in individuals aged between 12 and 59.
Computerized cognitive assessment aid for concussion is a new category for a device, which uses an individual's score(s) on a battery of cognitive tasks to provide an indication of the current level of cognitive function in response to concussion.
ImPACT Applications CEO Michael Wahlster said: "ImPACT Pediatric is a huge step forward for the industry and specifically for pediatric patients who are at-risk of concussion-related injuries.
"Unlike older age groups who are often baseline tested before injury, concussion management for young children is mostly reactive.
“ImPACT Pediatric allows for proactive baseline testing for well-child patients and insight into cognitive changes if an injury occurs.”
Around two million children are expected to suffer sports-related concussions each year, according to a study by researchers from the University of Washington, University of Colorado and Seattle Children's Research Institute.